MMAF

• Description:

  MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A[1][2][3].

• Product Name Alternative:

  Monomethylauristatin F

• UNSPSC:

  12352203

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  ADC Payload; Microtubule/Tubulin

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/mmaf.html

• Purity:

  99.97

• Solubility:

  DMSO : 140 mg/mL (ultrasonic)

• Smiles:

  CC(C)[C@H](NC)C(N[C@H](C(N([C@@H]([C@@H](C)CC)[C@H](OC)CC(N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(N[C@H](C(O)=O)CC2=CC=CC=C2)=O)=O)C)=O)C(C)C)=O

• Molecular Formula:

  C39H65N5O8

• Molecular Weight:

  731.96

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006 Jan-Feb;17 (1) :114-24.|[2]Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16 (9) :2562-70.|[3]Lee JJ, et al. Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy. Angew Chem Int Ed Engl. 2015 Oct 5;54 (41) :12020-4.|[4]Kim EG, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted CancerTherapeutics.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  ADC Related

• Clinical Information:

  No Development Reported

• Isoform:

  Auristatin

• Citation 01:

  J Control Release. 2018 May 10;277:48-56.|Mol Cancer Ther. 2023 Apr 3;22 (4) :459-470.|Mol Ther Nucleic Acids. 2018 Mar 2;10:227-236.|Patent. US20210393733A1.|Research Square Preprint. 2023 Dec 4.|Research Square Print. 2023 Jan 6th.|Target Oncol. 2019 Oct;14 (5) :577-590.|University of Minnesota. 2022 Sep.|Oncol Rep. 2021 Feb;45 (2) :776-785.

• CAS Number:

  [745017-94-1]